
Ocular Hypertension - Pipeline Insight, 2025
Description
DelveInsight’s, “Ocular Hypertension - Pipeline Insight, 2025” report provides comprehensive insights about 50+ companies and 75+ pipeline drugs in Ocular Hypertension pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Ocular Hypertension: Overview
Ocular hypertension is a condition characterized by elevated pressure inside the eye, which occurs when the aqueous humor, a fluid responsible for nourishing the eye and maintaining its shape, doesn't drain properly. Although individuals with ocular hypertension often experience no noticeable symptoms or changes to their vision, the condition can increase the risk of developing glaucoma, a more serious eye disorder that causes structural damage and potential vision loss. While ocular hypertension does not always progress to glaucoma, regular monitoring by an eye care professional is essential to detect any early signs of damage and manage the condition effectively. Lifestyle factors, such as diet and stress levels, may also play a role in managing eye pressure, though medication or other treatments may be necessary for some individuals. Early intervention can help prevent long-term damage and preserve vision.
Increased intraocular pressure can result from either an excess of fluid entering the eye or a reduced ability of the eye to drain fluid properly. Several conditions can interfere with the normal drainage of aqueous humor, leading to elevated pressure. One such cause is uveitis, an inflammation of the middle portion of the eye, which can affect fluid drainage. Pigment dispersion syndrome occurs when tiny pigment particles from the iris float around inside the eye, potentially blocking the trabecular meshwork, the primary drainage system for the aqueous humor. Pseudoexfoliation syndrome, characterized by the buildup of microscopic protein fibers within the eye, can also obstruct fluid flow. Other causes include the presence of tumors or large cataracts that block drainage pathways, damage caused by eye injury or surgery, and certain medications, particularly corticosteroids. Additionally, chronic angle-closure, in which the iris blocks the trabecular meshwork, can hinder the outflow of aqueous humor, increasing intraocular pressure.
Several factors can increase the risk of developing ocular hypertension. Individuals aged 40 or older are at greater risk, as are those with a family history of ocular hypertension or glaucoma. People with severe nearsightedness (myopia) or farsightedness (hyperopia) are also more prone to elevated eye pressure. Additionally, conditions like diabetes and high blood pressure can contribute to higher risk. Eye injuries, previous eye surgeries, or eye injections may also increase susceptibility. Long-term use of steroid medications is a known risk factor, as are specific eye conditions such as pigment dispersion syndrome and pseudoexfoliation syndrome. Certain medications, like topiramate, may also raise the likelihood of developing ocular hypertension.
Ocular hypertension doesn't always require treatment, but doctors assess the patient's risk of developing glaucoma over the next five to ten years to determine the best approach. If the risk is moderate to high, treatment is usually recommended to prevent damage to the optic nerve. If the risk is low, doctors typically prefer to monitor the condition instead. When treatment is necessary, the most common approach is prescribing eye drops to lower intraocular pressure by 20% to 25%. These drops can include prostaglandins, beta blockers, carbonic anhydrase inhibitors, alpha agonists, and netarsudil (a rho-kinase inhibitor). In some cases, laser surgery may be considered to help reduce intraocular pressure, although most patients won't require this intervention.
""Ocular Hypertension- Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Ocular Hypertension pipeline landscape is provided which includes the disease overview and Ocular Hypertension treatment guidelines. The assessment part of the report embraces, in depth Ocular Hypertension commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Ocular Hypertension collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Ocular Hypertension report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Ocular Hypertension Emerging Drugs
Further product details are provided in the report……..
Ocular Hypertension: Therapeutic Assessment
This segment of the report provides insights about the different Ocular Hypertension drugs segregated based on following parameters that define the scope of the report, such as:
Ocular Hypertension: Pipeline Development Activities
The report provides insights into different therapeutic candidates in Phase III, II, I, preclinical and discovery stage. It also analyses Ocular Hypertension therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Ocular Hypertension drugs.
Ocular Hypertension Report Insights
Current Treatment Scenario and Emerging Therapies:
Please Note: It will take 3-4 business days to complete the report upon order confirmation.
Geography Covered
- Global coverage
Ocular Hypertension: Overview
Ocular hypertension is a condition characterized by elevated pressure inside the eye, which occurs when the aqueous humor, a fluid responsible for nourishing the eye and maintaining its shape, doesn't drain properly. Although individuals with ocular hypertension often experience no noticeable symptoms or changes to their vision, the condition can increase the risk of developing glaucoma, a more serious eye disorder that causes structural damage and potential vision loss. While ocular hypertension does not always progress to glaucoma, regular monitoring by an eye care professional is essential to detect any early signs of damage and manage the condition effectively. Lifestyle factors, such as diet and stress levels, may also play a role in managing eye pressure, though medication or other treatments may be necessary for some individuals. Early intervention can help prevent long-term damage and preserve vision.
Increased intraocular pressure can result from either an excess of fluid entering the eye or a reduced ability of the eye to drain fluid properly. Several conditions can interfere with the normal drainage of aqueous humor, leading to elevated pressure. One such cause is uveitis, an inflammation of the middle portion of the eye, which can affect fluid drainage. Pigment dispersion syndrome occurs when tiny pigment particles from the iris float around inside the eye, potentially blocking the trabecular meshwork, the primary drainage system for the aqueous humor. Pseudoexfoliation syndrome, characterized by the buildup of microscopic protein fibers within the eye, can also obstruct fluid flow. Other causes include the presence of tumors or large cataracts that block drainage pathways, damage caused by eye injury or surgery, and certain medications, particularly corticosteroids. Additionally, chronic angle-closure, in which the iris blocks the trabecular meshwork, can hinder the outflow of aqueous humor, increasing intraocular pressure.
Several factors can increase the risk of developing ocular hypertension. Individuals aged 40 or older are at greater risk, as are those with a family history of ocular hypertension or glaucoma. People with severe nearsightedness (myopia) or farsightedness (hyperopia) are also more prone to elevated eye pressure. Additionally, conditions like diabetes and high blood pressure can contribute to higher risk. Eye injuries, previous eye surgeries, or eye injections may also increase susceptibility. Long-term use of steroid medications is a known risk factor, as are specific eye conditions such as pigment dispersion syndrome and pseudoexfoliation syndrome. Certain medications, like topiramate, may also raise the likelihood of developing ocular hypertension.
Ocular hypertension doesn't always require treatment, but doctors assess the patient's risk of developing glaucoma over the next five to ten years to determine the best approach. If the risk is moderate to high, treatment is usually recommended to prevent damage to the optic nerve. If the risk is low, doctors typically prefer to monitor the condition instead. When treatment is necessary, the most common approach is prescribing eye drops to lower intraocular pressure by 20% to 25%. These drops can include prostaglandins, beta blockers, carbonic anhydrase inhibitors, alpha agonists, and netarsudil (a rho-kinase inhibitor). In some cases, laser surgery may be considered to help reduce intraocular pressure, although most patients won't require this intervention.
""Ocular Hypertension- Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Ocular Hypertension pipeline landscape is provided which includes the disease overview and Ocular Hypertension treatment guidelines. The assessment part of the report embraces, in depth Ocular Hypertension commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Ocular Hypertension collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Ocular Hypertension R&D. The therapies under development are focused on novel approaches to treat/improve Ocular Hypertension.
This segment of the Ocular Hypertension report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Ocular Hypertension Emerging Drugs
- Sepetaprost: Santen Pharmaceutical
- NCX 470: Nicox Ophthalmics, Inc.
- QLS-111: Qlaris Bio, Inc.
- H-1337: Allysta Pharmaceuticals
- RTC-1119: Ripple Therapeutics
Further product details are provided in the report……..
Ocular Hypertension: Therapeutic Assessment
This segment of the report provides insights about the different Ocular Hypertension drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Ocular Hypertension
- There are approx. 50+ key companies which are developing the therapies for Ocular Hypertension. The companies which have their Ocular Hypertension drug candidates in the most advanced stage, i.e. Preregistration include, Santen Pharmaceutical.
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
- Molecule Type
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
- Product Type
Ocular Hypertension: Pipeline Development Activities
The report provides insights into different therapeutic candidates in Phase III, II, I, preclinical and discovery stage. It also analyses Ocular Hypertension therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Ocular Hypertension drugs.
Ocular Hypertension Report Insights
- Ocular Hypertension Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Ocular Hypertension drugs?
- How many Ocular Hypertension drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Ocular Hypertension?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Ocular Hypertension therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Ocular Hypertension and their status?
- What are the key designations that have been granted to the emerging drugs?
- Santen Pharmaceutical
- Nicox Ophthalmics, Inc.
- Allysta Pharmaceuticals
- Qlaris Bio, Inc
- Ripple Therapeutics
- Laboratoires Thea
- Ocular Therapeutix, Inc.
- Otsuka Beijing Research Institute
- Alcon Research
- AbbVie
- Glaukos Corporation
- MediPrint Ophthalmics
- Ocuphire Pharma
- Sepetaprost
- NCX 470
- QLS-111
- H-1337
- RTC-1119
- T4090
- OTX-TIC
- OPC-1085EL
- AR-17043
- AGN-193408 SR
- iDose TREX
- LL-BMT1
- Nyxol
Please Note: It will take 3-4 business days to complete the report upon order confirmation.
Table of Contents
280 Pages
- Introduction
- Executive Summary
- Ocular Hypertension: Overview
- Introduction
- Causes
- Pathophysiology
- Signs and Symptoms
- Diagnosis
- Treatment
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Ocular Hypertension– DelveInsight’s Analytical Perspective
- Late Stage Products (Preregistration)
- Comparative Analysis
- Sepetaprost: Santen Pharmaceutical
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- QLS-111: Qlaris Bio, Inc.
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Comparative Analysis
- Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Comparative Analysis
- RTC-1119: Ripple Therapeutics
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Ocular Hypertension Key Companies
- Ocular Hypertension Key Products
- Ocular Hypertension- Unmet Needs
- Ocular Hypertension- Market Drivers and Barriers
- Ocular Hypertension- Future Perspectives and Conclusion
- Ocular Hypertension Analyst Views
- Ocular Hypertension Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.